Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Do Hedge Funds Think of Akari Therapeutics PLC (ADR) (AKTX)?

The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings discloses the funds’ positions on September 30. We at Insider Monkey have made an extensive database of more than 700 of those elite funds and prominent investors’ filings. In this article, we analyze how these elite funds and prominent investors traded Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) based on those filings.

Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has seen an increase in enthusiasm from smart money in recent months with a total of 9 funds long the stock. At the end of this article we will also compare AKTX to other stocks including Trinity Biotech plc (ADR) (NASDAQ:TRIB), American Software, Inc. (NASDAQ:AMSWA), and Blount International, Inc. (NYSE:BLT) to get a better sense of its popularity.

Follow Akari Therapeutics Plc (NASDAQ:AKTX)
Trade (NASDAQ:AKTX) Now!

In the eyes of most traders, hedge funds are perceived as slow, old financial vehicles of yesteryear. While there are over 8000 funds trading at the moment, Our experts hone in on the top tier of this club, about 700 funds. These hedge fund managers preside over the majority of the hedge fund industry’s total capital, and by following their inimitable investments, Insider Monkey has identified various investment strategies that have historically beaten the broader indices. Insider Monkey’s small-cap hedge fund strategy outperformed the S&P 500 index by 12 percentage points per annum for a decade in their back tests.

Keeping this in mind, let’s take a glance at the recent action surrounding Akari Therapeutics PLC (ADR) (NASDAQ:AKTX).

What does the smart money think about Akari Therapeutics PLC (ADR) (NASDAQ:AKTX)?

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, James E. Flynn’s Deerfield Management has the largest position in Akari Therapeutics PLC (ADR) (NASDAQ:AKTX), worth close to $27.6 million, amounting to 1.1% of its total 13F portfolio. Sitting at the No. 2 spot is VHCP Management, managed by Anders Hove and Bong Koh, which holds an $12.7 million position; 3.2% of its 13F portfolio is allocated to the stock. Some other members of the smart money that are bullish consist of Julian Baker and Felix Baker’s Baker Bros. Advisors, Peter Kolchinsky’s RA Capital Management and Oleg Nodelman’s EcoR1 Capital.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.